explore -WSS

explore

author：hotspot 2025-10-01 22:57:32 - browse：3

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： First Opinion Podcast: Long Covid needs a new approach

focus

WSS

Biogen Alzheimer’s drug launch off to slow start

To avoid data mishandling cases, universities eye AI and other tools

What we’ve learned from the Aduhelm mess

PhRMA lawsuit over Medicare drug price negotiation tossed

Studies point to risks of excluding people with obesity from drug trials

Medical mystery: When a cough is not just a cough

knowledge

explore

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Vaccine advisory panel ACIP left half staffed by HHS

Affirmative action in medical school literally saved lives

Pharmacists can make shortage drugs, but at what cost?

Hollywood unions extend contract negotiations for actors

'Revelatory' study finds a smoking impact that remains after quitting

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA warns J&J's Abiomed: We will regulate your software

Cancer drug shortages should be causing more outrage

What we’ve learned from the Aduhelm mess

leisure time

What should King Charles tell the public about his cancer?

Researchers explore possible ties between long Covid, menopause

Biden report: The neurospychology of memory and aging

BioAge raises $170M for combination therapy with Zepbound

How digital tools helped lower hypertension in marginalized patients

First Opinion Podcast: Long Covid needs a new approach

hotspot

focus

focus

leisure time